West Pharmaceutical Services Inc. Common Stock (WST)
Stock · NYSE · Health Care
$383.81as of 10/16/2026
Price chart
Active signals
WST Signal Track Record
How signals performed across all stocks →What WST's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 32 | +1.7% | 53% | September 15, 2026 |
| Bollinger Band BreakoutActive now | 25 | +1.1% | 56% | September 15, 2026 |
| Bollinger Band Breakdown | 20 | +3.6% | 55% | August 28, 2026 |
| 200-Day Moving Average TouchActive now | 17 | -0.4% | 41% | March 31, 2026 |
| Any 20-session window (baseline) | +1.5% | 56% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About WST
West Pharmaceutical Services, Inc. designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates in two segments, Proprietary Products and Contract-Manufactured Products. The Proprietary Products segment offers stoppers and seals for injectable packaging systems; syringe and cartridge c…
- Sector
- Health Care
- Industry
- Medical/Dental Instruments
- Employees
- 10,800
- Website
- www.westpharma.com/
Fundamentals
- 1-day range
- $381.8$386.22
- Market cap
- $24.53B
- P/E (trailing)
- 48.71
- P/E (forward)
- 38.54
- EPS (trailing)
- $7.82
- Dividend yield
- 0.33%
- Beta
- 1.15
- Avg. volume
- 615.4K
- Ex-dividend date
- July 29, 2026
- Dividend pay date
- August 5, 2026
How West Pharmaceutical Services Inc. Common Stock Makes Money
Where the revenue actually goes — FY2025 annual results
Source: 10-K filed Feb 17, 2026 · via SEC EDGAR / Finnhub
Forecasts
16 analyst ratings
West Pharmaceutical Services Inc. Common Stock Competitors
Chosen by industry and closest market cap.
- WSTWest Pharmaceutical Services Inc. Common Stock$384.02▲ 0.26%Market cap $24.53BP/E 48.71$223.83$386
- DXCMDexCom Inc. Common Stock$86.04▼ 1.90%Market cap $31.33BP/E 32.73$54.11$92.59
- RMDResMed Inc. Common Stock$238.97▼ 1.35%Market cap $32.38BP/E 22.23$180.27$277.67
- BAXBaxter International Inc. Common Stock$25.28▼ 1.86%Market cap $13.96BP/E —$15.73$30
- GMEDGlobus Medical Inc. Class A Common Stock$76.71▼ 2.70%Market cap $11.01BP/E 19.14$56.96$101.4
- GKOSGlaukos Corporation Common Stock$164.84▼ 0.46%Market cap $10.09BP/E —$73.16$191.62
- PODDInsulet Corporation Common Stock$141.1▲ 1.68%Market cap $9.65BP/E 25.40$126.4$354.88
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| WST West Pharmaceutical Services Inc. Common Stock | $24.53B | 48.71 | $384.02 | ▲ 0.26% | $223.83$386 |
| DXCM DexCom Inc. Common Stock | $31.33B | 32.73 | $86.04 | ▼ 1.90% | $54.11$92.59 |
| RMD ResMed Inc. Common Stock | $32.38B | 22.23 | $238.97 | ▼ 1.35% | $180.27$277.67 |
| BAX Baxter International Inc. Common Stock | $13.96B | — | $25.28 | ▼ 1.86% | $15.73$30 |
| GMED Globus Medical Inc. Class A Common Stock | $11.01B | 19.14 | $76.71 | ▼ 2.70% | $56.96$101.4 |
| GKOS Glaukos Corporation Common Stock | $10.09B | — | $164.84 | ▼ 0.46% | $73.16$191.62 |
| PODD Insulet Corporation Common Stock | $9.65B | 25.40 | $141.1 | ▲ 1.68% | $126.4$354.88 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- Meta, JPMorgan, West Pharmaceutical And More: CNBC’s ‘Final Trades’benzinga · 10/14/2026
- ANGO Q1 Earnings Beat Estimates on Med Tech Growth, Revenues Up Y/YYahoo · 10/9/2026
- Reasons to Hold Veeva Systems Stock in Your Portfolio for NowYahoo · 10/9/2026
- Smith+Nephew Launches CARTIHEAL Implant Across Key European MarketsYahoo · 10/8/2026
- Here's Why You Should Retain WAT Stock in Your Portfolio for NowYahoo · 10/8/2026
- West to Host Third-Quarter 2026 Conference CallYahoo · 10/8/2026
- West Pharmaceutical Services Needs Faster Earnings Growth To Justify Its PriceSeekingAlpha · 10/8/2026
- West Pharmaceutical Services (WST) Stock Could Be 17% Overvalued As Cash Flow Falls ShortYahoo · 10/8/2026
- Reasons to Retain Fresenius Medical Stock in Your Portfolio for NowYahoo · 10/7/2026
Insider Activity
Insider Actions →- Janet Brutschea Haugen · September 30, 2026 · Grant44 @ $370.76
- Annette F. Favorite · September 15, 2026 · Option Exercise2.5K @ $89.64
- Annette F. Favorite · September 15, 2026 · Sale2.5K @ $365
- Annette F. Favorite · September 14, 2026 · Option Exercise2.5K @ $89.64
- Annette F. Favorite · September 14, 2026 · Sale2.5K @ $355
- Annette F. Favorite · September 11, 2026 · Option Exercise2.5K @ $89.64
- Annette F. Favorite · September 11, 2026 · Sale2.5K @ $345
- Michel Lagarde · September 8, 2026 · Grant3.6K
- Michel Lagarde · September 8, 2026 · Grant5.0K
- Michel Lagarde · September 8, 2026 · Grant6.2K
- Michel Lagarde · September 8, 2026 · Grant12.1K
- Michel Lagarde · September 8, 2026 · Grant11.1K
- Michel Lagarde · September 8, 2026 · Grant13.9K
- Annette F. Favorite · September 8, 2026 · Option Exercise2.5K @ $89.64
- Annette F. Favorite · September 8, 2026 · Option Exercise2.8K @ $83.47
Institutional Ownership
March 31, 2026
- Total shares held
- 65.89M
- Total value held
- $15.32B
- Institutional holders
- 744
- Unknown6.84M
- Unknown4.68M
- Unknown3.29M
- Unknown2.66M
- Unknown2.47M
- Unknown2.34M
- Unknown2.24M
- Unknown1.91M
- Unknown1.46M
- Unknown1.34M
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
West Pharmaceutical Services noted in analyst upgrade and market rally
West Pharmaceutical Services has risen about 36% year-to-date, drawing attention in recent market round-ups. TD Cowen kept its positive stance and lifted its price target to $420, citing the company's performance. The stock also appeared in CNBC’s final‑trade segment and in a dividend‑growth stock list, highlighting investor interest.
West Pharmaceutical Services noted in analyst upgrade and market rally. West Pharmaceutical Services has risen about 36% year-to-date, drawing attention in recent market round-ups. TD Cowen kept its positive stance and lifted its price target to $420, citing the company's performance. The stock also appeared in CNBC’s final‑trade segment and in a dividend‑growth stock list, highlighting investor interest.